StockData
Bionano Genomics, Inc. logo

Bionano Genomics, Inc. (BNGO) stock

BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3083% below fair value
$0.95+0.01 (+1.29%)

Close on Nov 17, 2026Market cap $11.21MP/E –Yield –

Bionano Genomics, Inc. grew revenue 10.0% to $30.18M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $11.21M.

Revenue
$30.18M
+10.0% vs. a year earlier
Operating income
-$32.19M
TTM Q2 2026
EPS, diluted
-$3.76
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$11.21M
P/E ratio
–
Price to sales
0.37
Price to book
0.35
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$30.18M
Net income
-$32.16M
EPS, diluted
-$3.76
Book value per share
$2.74
Diluted shares
12M

Trading

Next earnings
Mar 22, 2027 (estimated, during market hours)
Previous close
$0.94
Open
$0.95
Day's range
$0.95 – $0.97
Volume
72,847
Average volume (20 days)
257,273
52-week range
$0.93 – $2.23
RSI (14 days)
31.2
Volatility (1 year)
64.0%
Relative volume
0.10×

Market cap history

Month-end market cap since 2018, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodBNGOS&P 500DifferenceBNGO per yearS&P 500 per year
1 month-23.8%-4.0%−19.8 pts
3 months-20.0%-5.0%−15.0 pts
Year to date-37.8%+8.2%−46.0 pts
1 year-36.5%+11.2%−47.7 pts
3 years-98.8%+68.5%−167.3 pts-77.3%+19.0%
5 years-100.0%+67.3%−167.2 pts-79.8%+10.8%

Ten years at a glance

Fiscal years 2016 to 2025 and trailing twelve months, USD

Revenue

$30.18M+10.0% YoY

Gross profit

$14.34M+934.3% YoY

Operating income

-$32.19M

Net income

-$32.16M

EPS, diluted

-$3.76

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Bionano Genomics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Bionano Genomics

Laboratory Analytical Instruments

Bionano Genomics, Inc. is a life sciences company that provides optical genome mapping solutions for genomic analysis and cytogenetic research. The company offers imaging instruments, notably the Saphyr and Stratys systems, along with related consumables, testing services, and VIA data analysis software. It conducts business through a single reportable segment and operates subsidiaries including BioDiscovery, Purigen Biosystems, and Lineagen, which operates as Bionano Laboratories. Its customers include researchers, cytogeneticists, and laboratories performing routine genomic analysis.

Company profile, executives and history

Bionano Genomics stock: common questions

What is Bionano Genomics's stock price?

BNGO closed at $0.95 on Nov 17, 2026, up 1.29% on the day. Over the past 52 weeks it traded between $0.93 and $2.23.

What is Bionano Genomics's market cap?

Bionano Genomics was worth $11.21M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is BNGO's P/E ratio?

Bionano Genomics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.76), so it has no meaningful P/E ratio.

How much revenue does Bionano Genomics make?

Bionano Genomics reported revenue of $30.18M for the twelve months to Jun 30, 2026, up 10.0% from a year earlier.

Does Bionano Genomics pay a dividend?

No. Bionano Genomics has not paid a cash dividend over the last twelve months.

When does Bionano Genomics report earnings next?

Bionano Genomics is expected to report Q4 FY2026 results on Mar 22, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.

How has BNGO stock performed over the past year?

Including dividends, BNGO returned -36.5% over the past year, against +11.2% for the S&P 500.

How many BNGO shares are sold short?

1M shares were sold short at the latest FINRA report, 12.00% of the float, or 7.4 days of average trading volume.

Who are Bionano Genomics's competitors?

Companies most similar to Bionano Genomics by business, industry and size include SEER, RPID, PACB, PRPO, HBIO.

See a number that looks wrong?